Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure

被引:38
作者
Perianayagam, MC [1 ]
Murray, SL [1 ]
Balakrishnan, VS [1 ]
Guo, DQ [1 ]
King, AJ [1 ]
Pereira, BJG [1 ]
Jaber, BL [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Nephrol, Tupper Res Inst, Dept Med, Boston, MA 02111 USA
来源
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 2000年 / 136卷 / 04期
关键词
D O I
10.1067/mlc.2000.109318
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Apoptosis, or programmed cell death, is an active form of cell death that is initiated by a number of stimuli and is intricately regulated, Apoptosis in both excessive and reduced amounts has pathophysiologic implications. Accelerated programmed cell death has been observed in leukocytes among patients with chronic renal failure (CRF). This has been ascribed in part to the retention of uremic toxins. The Fas/Fas ligand (FasL) system is a key regulatory apoptotic pathway, Membrane-bound Fas is a cell-surface receptor that transduces apoptosis after interaction with membrane-bound or soluble FasL (sFasL). By contrast, soluble Fas (sFas) binds sFasL and inhibits its activity. In an attempt to examine the balance between these soluble factors in uremia, we measured soluble sFas and sFasL levels in the serum of healthy control subjects and patients with various degrees of CRF and examined the distribution of the various molecular mass fractions of these proteins in uremic serum. In brief, serum was obtained from 15 healthy volunteers, 17 patients with CRF, 11 patients undergoing maintenance hemodialysis (HD), and 7 patients undergoing peritoneal dialysis (PD). Serum sFas and sFasL were measured by enzyme-linked immunosorbent assay, and their molecular distribution was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblot. Compared with results in healthy control subjects, sFas levels were significantly higher in patients with CRF and in patients undergoing dialysis. There was a significant inverse correlation between sFas levels and creatinine clearance. Serum sFasL levels were not different among the four groups. However, the sFas-to-sFasL ratio was significantly lower in healthy control subjects as compared with patients with CRF and patients undergoing dialysis. Immunoblots and densitometric analyses of sFas and sFasL depicted a known 48-kd sFas, a known 27-kd sFasL, and a 60-kd sFas-sFasL protein aggregate signal. In conclusion, serum sFas levels are increased in patients with various degrees of CRF and may bind circulating sFasL, thereby minimizing mediation of cellular apoptosis.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 29 条
  • [1] BLAND LA, 1995, AAMI STANDARD RECOMM, V3, P293
  • [2] APOPTOSIS AND DISEASE
    CARSON, DA
    RIBEIRO, JM
    [J]. LANCET, 1993, 341 (8855) : 1251 - 1254
  • [3] CASCINO I, 1995, J IMMUNOL, V154, P2706
  • [4] Cendoroglo M, 1999, J AM SOC NEPHROL, V10, P93
  • [5] PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE
    CHENG, JH
    ZHOU, T
    LIU, CD
    SHAPIRO, JP
    BRAUER, MJ
    KIEFER, MC
    BARR, PJ
    MOUNTZ, JD
    [J]. SCIENCE, 1994, 263 (5154) : 1759 - 1762
  • [6] DEBATIN KM, 1993, BLOOD, V81, P2972
  • [7] Apoptosis of monocytes cultured from long-term hemodialysis patients
    Heidenreich, S
    Schmidt, M
    Bachmann, J
    Harrach, B
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (03) : 792 - 799
  • [8] The expression of genes modulating programmed cell death in normal human polymorphonuclear neutrophils
    Hsieh, SC
    Huang, MH
    Tsai, CY
    Tsai, YY
    Tsai, ST
    Sun, KH
    Yu, HS
    Han, SH
    Yu, CL
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (03) : 700 - 706
  • [9] THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS
    ITOH, N
    YONEHARA, S
    ISHII, A
    YONEHARA, M
    MIZUSHIMA, S
    SAMESHIMA, M
    HASE, A
    SETO, Y
    NAGATA, S
    [J]. CELL, 1991, 66 (02) : 233 - 243
  • [10] Modulation of neutrophil apoptosis by uremic plasma during hemodialysis
    Jaber, BL
    Balakrishnan, VS
    Cendoroglo, MN
    Perianayagan, MC
    King, AJ
    Pereira, BJG
    [J]. BLOOD PURIFICATION, 1998, 16 (06) : 325 - 335